Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients

Mircescu, Gabriel; Gârneaţă, Liliana; Ciocalteu, Alexandru; Golea, O; Gherman-Caprioara, Mirela; Capşa, D; Moţa, E; Gusbeth‐Tatomir, Paul; Ghenu, Adrian; Bălută, Simona; Constantinovici, Niculae; Covic, Adrian

doi:10.1053/j.ajkd.2006.05.030

Cited by 8 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Portoles at al., 2005) Erythropoietin beta could be better metabolically and economically used when applied subcutaneously 3x weekly or 1x weekly, even 1 x in two weeks. (Miroescu et al, 2006) Darberythropoietin alfa is administered once weekly or once in two weeks, even at four weeks. (Carrera et al, 2006;Fang & Chang, 2009) But in patients on haemodialysis erythropoietin is given predominantly intravenously in developed countries, because it has also local side effects as inflammations, haemorrhage or calciphylaxia, and also has historical risk of pure red cell aplasia.…”

Section: Administration Of Erythropoietinmentioning

confidence: 99%

After the Kidney Transplant - The Patients and Their Allograft

Ortíz¹,

Andre²

2011

View full text Add to dashboard Cite

Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published articles. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.

show abstract

Section: Administration Of Erythropoietinmentioning

confidence: 99%

After the Kidney Transplant - The Patients and Their Allograft

Ortíz¹,

Andre²

2011

View full text Add to dashboard Cite

show abstract

“…Erythropoietin beta could be better metabolically and economically used when applied subcutaneously 3x weekly or 1x weekly, even 1 x in two weeks. (Miroescu et al, 2006) Darberythropoietin alfa is administered once weekly or once in two weeks, even at four weeks. (Carrera et al, 2006;Fang & Chang, 2009) But in patients on haemodialysis erythropoietin is given predominantly intravenously in developed countries, because it has also local side effects as inflammations, haemorrhage or calciphylaxia, and also has historical risk of pure red cell aplasia.…”

Section: Indicationsmentioning

confidence: 99%

Characteristics of Anaemia Management in Patients with Chronic Kidney Disease

Puretić¹

2011

After the Kidney Transplant - The Patients and Their Allograft

View full text Add to dashboard Cite

“…Another important advantage of iv administration is a longer half-life (24 h vs 9 h) [158,159] . Daily sc EPO is more effective than administration 2-3 times weekly [160] , although administration less frequently than every 2 wk is also effective [161][162][163] . Discomfort at the injection site is minimal.…”

Section: Dosage Monitoring and Controlmentioning

confidence: 99%

Use of agents stimulating erythropoiesis in digestive diseases

López¹,

Sicilia²,

García³

2009

WJG

View full text Add to dashboard Cite

Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as first choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same efficacy and safety.

show abstract

Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients

Cited by 8 publications

References 20 publications

After the Kidney Transplant - The Patients and Their Allograft

After the Kidney Transplant - The Patients and Their Allograft

Characteristics of Anaemia Management in Patients with Chronic Kidney Disease

Use of agents stimulating erythropoiesis in digestive diseases

Contact Info

Product

Resources

About